Transgenes licenced oncolytic virus fail... SillaJen, the licensor for French immunoncology specialist Transgene SA, has stopped enrolment into the Phase III Phocus trial after an Independent Data Review Comittee predicted the study endpoint … more ➔
Wellington Partners launch €210m Life Sc...Wellington Partners has closed its largest Life Sciences Fund ever. The VC specialist outperformed its intial target of raising €120m to €150m and closed at €210m. more ➔
Alizé Pharma 3 bags largest EU financing...Venture Captital specialist LSP led a €67m Series A financing in peptide developer Alizé Pharma 3. more ➔
Better TNF? receptor blockers on the horiz...Two research teams have unraveled the complex dynamics of TNF? receptor signaling and have identified compounds that may be safer than current treatments. more ➔
AgroSavfe raises €35m in Series C financ...Plant protection specialist AgroSavfe will use the funds of a €35m Series C financing to push the development, registration and commercial scale production of its biofungicides and bio-insecticide … more ➔
European Commission approves ten GMOs The European Commission has authorised ten genetically modified products. more ➔
Zambon heading to US market with €500m a...Zambon is set to acquire respiratory company Breath Therapeutics for up to €500m to complement its respiratory pipeline and get access to the US market. more ➔
Gut microbiome boosts muscle strengthSwedish researchers have demonstrated that the gut microbiome can significantly affect the proper development and strength of skeletal muscle. more ➔
3P Pharma finds new major investor Pamplona-based CDMO 3P Biopharmaceuticals (3P) has announced Keensight Capital as its new major investor after previous major investor Infarco is refocussing on international expansion. By providing … more ➔
Curetis lower respiratory tract panel read...Molecular diagnostics expert Curetis NV has filed for US FDA clearance of Unyvero LRT to speed up diagnosis of patients with lower respiratory tract (LRT) infections. more ➔